GSK
Latest statistics and disclosures from GSK's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CRSP, VIR, WVE, BNTX, IDYA, and represent 85.38% of GSK's stock portfolio.
- Added to shares of these 1 stock: WVE (+$68M).
- Started 1 new stock position in WVE.
- Reduced shares in these 3 stocks: Wave Life Sciences (-$106M), CRSP (-$34M), BNTX (-$22M).
- Sold out of its position in Wave Life Sciences.
- GSK was a net seller of stock by $-94M.
- GSK has $497M in assets under management (AUM), dropping by -17.47%.
- Central Index Key (CIK): 0001131399
Tip: Access up to 7 years of quarterly data
Positions held by GSK consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for GSK
GSK holds 13 positions in its portfolio as reported in the September 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Crispr Therapeutics Namen Akt (CRSP) | 29.0 | $144M | -19% | 2.6M | 55.32 |
|
| Vir Biotechnology (VIR) | 19.2 | $96M | 8.6M | 11.18 |
|
|
| Wave Life Sciences SHS (WVE) | 13.6 | $68M | NEW | 18M | 3.70 |
|
| Biontech Se Sponsored Ads (BNTX) | 13.2 | $66M | -24% | 669k | 98.30 |
|
| Ideaya Biosciences (IDYA) | 10.3 | $51M | 1.3M | 38.42 |
|
|
| Cytokinetics Com New (CYTK) | 4.5 | $22M | 340k | 65.91 |
|
|
| Lyell Immunopharma Com New (LYEL) | 3.0 | $15M | 1.5M | 9.79 |
|
|
| Spero Therapeutics (SPRO) | 2.2 | $11M | 9.2M | 1.21 |
|
|
| Nkarta (NKTX) | 1.7 | $8.3M | 3.2M | 2.62 |
|
|
| Fulcrum Therapeutics (FULC) | 1.3 | $6.6M | 1.8M | 3.70 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 1.1 | $5.6M | 1.5M | 3.68 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.4 | $2.0M | 272k | 7.53 |
|
|
| CVRX (CVRX) | 0.4 | $1.8M | 1.0M | 1.75 |
|
Past Filings by GSK
SEC 13F filings are viewable for GSK going back to 2026
- GSK 2026 Q3 filed Nov. 5, 2026
- GSK 2026 Q2 filed Aug. 13, 2026